Immix Biopharma, Inc. cash flow to debt ratio of -2.23K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Immix Biopharma, Inc.'s free cash flow has decreased 56.37% from $-15.77M last year to $-24.66M, signaling decreasing performance

Immix Biopharma, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Immix Biopharma, Inc.'s debt has decreased relative to shareholder equity from 0.08 last year to 0.01 today, signaling strengthened financials

Immix Biopharma, Inc. has negative EBITDA, making leverage ratio unreliable

Immix Biopharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Immix Biopharma, Inc. has insufficient data to evaluate this check.

Immix Biopharma, Inc.'s short-term assets of $101.24M exceed its short-term liabilities of $10.11M

Immix Biopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Immix Biopharma, Inc.'s return on equity of -73.23%, is lower than 15.00%, indicating bad performance

Immix Biopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Immix Biopharma, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Immix Biopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Immix Biopharma, Inc. has negative free cash flow, indicating cash burn

Immix Biopharma, Inc.'s yearly earnings has decreased 36.21% since last year from $-21.61M to $-29.44M, signaling decreasing performance

Immix Biopharma, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -42.25% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Immix Biopharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Immix Biopharma, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Immix Biopharma, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Immix Biopharma, Inc. is overvalued relative to its fair value price of 1.39 based on Discounted Cash Flow model

Immix Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immix Biopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Immix Biopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Immix Biopharma, Inc. has insufficient data to evaluate this check.

Immix Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immix Biopharma, Inc. has a price-to-book ratio of 4.53x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Immix Biopharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue